[{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMP4297","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for IMP4297
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target